Tucatinib 150 mg and its Potential Role in Combining Targeted Therapies for Breast Cancer Treatment in India.
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjHK5kPhvvpS63ryZeQp1MHf5LghZ0XuAxNOh_K-0gGufPtzMhQE3xCRWrgURCFdSOrPpxjSYovxRNMEpzq7uzUebHjc7J4ve7paTNTWQthuRsS_nfsDF6mT32sOXQ41LgTbp65hOmc03-k9xRKdsvKbn0qcSkSDm-PyWP5zHWYGrGkGQbKs2Dx4UuoFQ4f/w587-h307/impomed%20healthcare%20(1).png)
Introduction:- Breast cancer is one of the most common types of cancer affecting women worldwide, including India. While early-stage breast cancer can often be treated with surgery and radiation therapy, advanced or metastatic breast cancer poses a bigger challenge for patients and healthcare providers. Targeted therapies that specifically attack cancer cells while sparing healthy tissue have revolutionized breast cancer treatment in recent years. Tucatinib 150 mg is a newly approved targeted therapy for HER2-positive metastatic breast cancer that has shown promise in clinical trials and has the potential to be used in combination with other targeted therapies to improve patient outcomes. The Role of Targeted Therapies in Breast Cancer Treatment:- Targeted therapies are drugs that interfere with specific molecules involved in the growth and survival of cancer cells. They differ from chemotherapy, which works by killing rapidly dividing cells, both cancerous and healthy. While chemoth